NON-DIABETOGENIC THERAPY USING A 20KDA PLACENTAL GROWTH HORMONE VARIANT

摘要

Embodiments of the present invention provide improved methods of treating conditions requiring human growth hormone (hGH) therapy, whereby the beneficial effects of hGH such as growth promotion and lipolysis are retained and unwanted properties such as insulin resistance are reduced or eliminated. In particular, embodiments of this invention are directed to methods of treatment whereby the diabetogenic side effects of conventional hGH treatment are reduced. The methods include the use of the growth hormone variant; 20kDa hGH-V in the treatment of conditions that are currently treated with hGH or that have the potential to be treated with hGH.